|
|
xi | |
Preface |
|
xvii | |
|
1 Metal nanoparticles toxicity: role of physicochemical aspects |
|
|
1 | (12) |
|
|
|
1 | (1) |
|
1.2 Mechanisms of metallic nanoparticles toxicity |
|
|
2 | (1) |
|
1.3 Effect of physicochemical properties on toxicity of metallic nanoparticles |
|
|
3 | (6) |
|
|
9 | (1) |
|
|
9 | (4) |
|
2 Erythrocytes modified (coated) gold nanoparticles for effective drug delivery |
|
|
13 | (18) |
|
|
|
|
|
13 | (1) |
|
2.2 Nanotechnology and their advancement |
|
|
14 | (1) |
|
2.3 Nanosize passage from micro to nanoparticles |
|
|
15 | (2) |
|
2.4 Why modern therapeutics diverging to nanoscales? |
|
|
17 | (1) |
|
2.5 Nanomaterials and their exploded applications |
|
|
17 | (1) |
|
2.6 Metallic nanoparticles |
|
|
18 | (1) |
|
2.7 Cells based drug delivery system |
|
|
18 | (2) |
|
2.8 Blood cells based derived drug delivery system |
|
|
20 | (1) |
|
|
21 | (2) |
|
2.10 Erythrocytes modified (coated) gold nanoparticles cargo |
|
|
23 | (3) |
|
2.11 Application of erythrocytes coated gold nanoparticles |
|
|
26 | (1) |
|
|
26 | (1) |
|
|
27 | (4) |
|
3 Biosynthesized metal nanoparticles as potential Alzheimer's disease therapeutics |
|
|
31 | (12) |
|
|
|
|
|
|
|
|
31 | (1) |
|
3.2 Mechanisms and popular hypothesis of Alzheimer's disease |
|
|
32 | (1) |
|
3.3 Neurodegenerative disorders and status of Alzheimer's disease |
|
|
33 | (1) |
|
3.4 Epidemiology/prevalence, continent-based statistics of Alzheimer's disease |
|
|
33 | (1) |
|
3.5 Present therapeutic issues, concerns, disadvantages of Alzheimer's disease therapies |
|
|
34 | (2) |
|
3.6 Nanomedicines for Alzheimer's disease with specific reference to the metal nanoparticles |
|
|
36 | (1) |
|
3.7 Biogenic nanoparticles as promising Alzheimer's disease theranostic agents |
|
|
37 | (2) |
|
3.8 Conclusion and future prospects |
|
|
39 | (1) |
|
|
39 | (4) |
|
4 Gold nanoparticles in cancer diagnosis and therapy |
|
|
43 | (16) |
|
|
|
|
|
|
43 | (2) |
|
|
45 | (1) |
|
4.3 Gold nanoparticles in cancer therapy and diagnosis |
|
|
46 | (6) |
|
4.4 Gold nanoparticles in clinical trials |
|
|
52 | (1) |
|
4.5 Safety concerns of gold nanoparticles |
|
|
52 | (1) |
|
|
53 | (1) |
|
|
53 | (6) |
|
5 Gold nanorods: new generation drug delivery platform |
|
|
59 | (26) |
|
|
|
|
|
|
59 | (2) |
|
|
61 | (1) |
|
|
62 | (7) |
|
|
69 | (1) |
|
5.5 Self-assembly of gold nanorods |
|
|
69 | (2) |
|
5.6 Gold nanorods applications in diagnostics |
|
|
71 | (4) |
|
5.7 Gold nanorod applications in drug delivery |
|
|
75 | (4) |
|
|
79 | (1) |
|
|
80 | (5) |
|
6 Surface engineered gold nanorods: intelligent delivery system for cancer therapy |
|
|
85 | (14) |
|
|
|
|
|
|
|
|
85 | (2) |
|
|
87 | (7) |
|
|
94 | (1) |
|
|
95 | (4) |
|
7 Role of gold- and silver-based nanoparticles in stem cells differentiation |
|
|
99 | (20) |
|
|
|
|
|
|
|
99 | (1) |
|
7.2 Effect on osteogenic differentiation |
|
|
100 | (3) |
|
7.3 Effect on chondrogenic differentiation |
|
|
103 | (1) |
|
7.4 Effect on adipogenic differentiation |
|
|
104 | (1) |
|
7.5 Role of nanoparticles in neuronal differentiation |
|
|
105 | (1) |
|
7.6 Role of nanoparticles in cardiac differentiation |
|
|
105 | (1) |
|
7.7 Effect on stem cells growth and proliferation |
|
|
106 | (1) |
|
7.8 Effect on reactive oxygen species |
|
|
107 | (1) |
|
7.9 Nanoparticles in wound healing |
|
|
108 | (1) |
|
7.10 Nanoparticles in cancer stem cells |
|
|
109 | (2) |
|
7.11 Cytotoxicity of nanoparticles on stem cells |
|
|
111 | (1) |
|
|
112 | (1) |
|
|
112 | (7) |
|
8 Nanosilver at the interface of biomedical applications, toxicology, and synthetic strategies |
|
|
119 | (22) |
|
|
|
|
|
|
|
120 | (3) |
|
8.2 Synthetic strategies of silver nanomaterials |
|
|
123 | (2) |
|
|
125 | (2) |
|
8.4 Biomedical applications of silver nanomaterials |
|
|
127 | (2) |
|
8.5 Toxicology of silver nanomaterials |
|
|
129 | (5) |
|
8.6 Summary and future perspectives |
|
|
134 | (1) |
|
|
134 | (7) |
|
9 Silver nanoparticles: a promising nanoplatform for targeted delivery of therapeutics and optimized therapeutic efficacy |
|
|
141 | (34) |
|
|
|
|
|
|
141 | (2) |
|
9.2 Biomedical applications of silver nanoparticles |
|
|
143 | (20) |
|
9.3 Summary and future prospects |
|
|
163 | (2) |
|
|
165 | (1) |
|
|
165 | (8) |
|
|
173 | (2) |
|
10 Bactericidal potentials of silver nanoparticles: novel aspects against multidrug resistance bacteria |
|
|
175 | (14) |
|
|
|
|
|
|
|
|
|
175 | (1) |
|
10.2 Mechanisms for bacterial antibiotic resistance |
|
|
176 | (1) |
|
10.3 Silver nanoparticles |
|
|
177 | (1) |
|
10.4 Antibacterial spectrum of silver nanoparticles |
|
|
178 | (1) |
|
10.5 Antibacterial spectrum of silver nanoparticles against multidrug resistance bacteria |
|
|
179 | (1) |
|
10.6 Mechanisms of silver nanoparticles bactericidal activity |
|
|
180 | (4) |
|
|
184 | (1) |
|
|
184 | (5) |
|
11 Magnetic nanoparticles: drug delivery and bioimaging applications |
|
|
189 | (26) |
|
|
|
|
|
|
189 | (4) |
|
11.2 Synthesis of magnetic nanoparticles |
|
|
193 | (4) |
|
11.3 Drug delivery and bioimaging applications |
|
|
197 | (10) |
|
|
207 | (1) |
|
|
208 | (7) |
|
12 Surface functionalized magnetic nanoparticles for targeted cancer therapy and diagnosis |
|
|
215 | (22) |
|
|
|
|
|
|
|
|
216 | (1) |
|
12.2 Considerations for magnetic nanoparticles design |
|
|
217 | (3) |
|
12.3 Functionalization of target specific magnetic nanoparticles |
|
|
220 | (5) |
|
12.4 Surface functionalization chemistry |
|
|
225 | (3) |
|
12.5 Magnetic nanoparticles targeting strategies and diagnosis |
|
|
228 | (3) |
|
|
231 | (1) |
|
|
232 | (4) |
|
|
236 | (1) |
|
13 Clinical implications of metals-based drug-delivery systems |
|
|
237 | (22) |
|
|
|
13.1 Nanotechnology: an introduction |
|
|
237 | (1) |
|
13.2 Types of nanoparticles |
|
|
238 | (5) |
|
13.3 Biomedical applications of metal nanoparticles |
|
|
243 | (8) |
|
13.4 Drawbacks of nanoparticles in drug-delivery system |
|
|
251 | (1) |
|
|
252 | (1) |
|
|
253 | (6) |
|
14 pH-sensitive drug delivery systems |
|
|
259 | (20) |
|
|
|
|
|
|
259 | (2) |
|
14.2 Classification of pH-sensitive drug delivery systems |
|
|
261 | (7) |
|
14.3 Synthesis of pH-sensitive drug delivery systems |
|
|
268 | (1) |
|
14.4 Structure and architecture of pH-sensitive drug delivery systems |
|
|
269 | (2) |
|
14.5 Applications of pH-sensitive drug delivery systems at different levels |
|
|
271 | (4) |
|
|
275 | (1) |
|
|
276 | (3) |
|
15 Ionic liquid-based colloidal nanoparticles: applications in organic synthesis |
|
|
279 | (22) |
|
|
|
|
|
|
280 | (2) |
|
15.2 Classes of ionic liquids |
|
|
282 | (4) |
|
|
286 | (1) |
|
15.4 Classification of nanoparticles |
|
|
286 | (3) |
|
15.5 Synthesis of nanoparticles |
|
|
289 | (6) |
|
|
295 | (1) |
|
|
296 | (5) |
|
16 Biomedical applications of magnetic nanoparticles |
|
|
301 | (28) |
|
|
|
|
|
302 | (1) |
|
16.2 Synthesis of magnetic nanoparticles |
|
|
303 | (6) |
|
16.3 Surface modification of magnetic nanoparticles |
|
|
309 | (7) |
|
16.4 Biomedical applications of magnetic nanoparticles |
|
|
316 | (6) |
|
|
322 | (1) |
|
|
323 | (6) |
Index |
|
329 | |